
Approved PATHWAYS Trial for Gender-Questioning Children Sets Minimum Age of 11
The Medicines and Healthcare products Regulatory Agency (MHRA) has introduced new minimum age requirements for participants in the PATHWAYS Trial, a landmark study examining the effects of puberty blockers in young people experiencing gender incongruence. As researchers seek to address evidence gaps identified by the Cass Review, the study could play a pivotal role in shaping future NHS policy and clinical decision-making on gender-related healthcare.










